Dr. Hashmi on Immunotherapy in Prostate Cancer

Video

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

As in many other cancers, immunotherapy is another available pillar of treatment, says Hashmi. Prostate cancer is a very immunogenic disease, and neoantigens are produced that can be targeted. Single-agent immunotherapy has induced response rates of approximately 10%. Combination therapies are now being explored in an attempt to further enhance response rates. Some of these strategies include dual immunotherapeutic approaches as well as immunotherapy in combination with androgen suppression, explains Hashmi.

In addition to developing synergistic combinations, Hashmi notes that physicians have to identify specific genes through genomic-based testing to further personalize treatments. Even with these advances, immunotherapy will be restricted to certain subsets of patients, states Hashmi.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD